230 related articles for article (PubMed ID: 1649813)
1. Interleukin-2-inducible killer activity and its regulation by blood monocytes from autologous lymphocytes of lung cancer patients.
Sone S; Kunishige E; Fawzy F; Yanagawa H; Nii A; Maeda K; Atagi S; Heike Y; Nishioka Y; Mizuno K
Jpn J Cancer Res; 1991 Jun; 82(6):716-23. PubMed ID: 1649813
[TBL] [Abstract][Full Text] [Related]
2. Phenotypes and lymphokine-activated killer activity of pleural cavity lymphocytes of lung cancer patients without malignant effusion.
Takahashi K; Sone S; Kimura S; Ogura T; Monden Y
Chest; 1993 Jun; 103(6):1732-8. PubMed ID: 8404092
[TBL] [Abstract][Full Text] [Related]
3. Lymphokine-activated killer (LAK) cell activity in tumor-infiltrating lymphocytes from non-small cell lung cancer.
Pisani RJ; Krco CJ; Wold LE; McKean DJ
Am J Clin Pathol; 1989 Oct; 92(4):435-46. PubMed ID: 2552792
[TBL] [Abstract][Full Text] [Related]
4. Lymphokine-activated killer induction and its regulation by macrophages in malignant pleural effusions.
Yanagawa H; Sone S; Nii A; Fukuta K; Nakanishi M; Maeda K; Honda M; Ogura T
Jpn J Cancer Res; 1989 Dec; 80(12):1220-7. PubMed ID: 2516849
[TBL] [Abstract][Full Text] [Related]
5. Up- and down-regulation of human lymphokine (IL-2)-activated killer cell induction by monocytes, depending on their functional state.
Nii A; Sone S; Utsugi T; Yanagawa H; Ogura T
Int J Cancer; 1988 Jan; 41(1):33-40. PubMed ID: 2826345
[TBL] [Abstract][Full Text] [Related]
6. Up-regulation by granulocyte-macrophage colony-stimulating factor (GM-CSF) of induction of lymphokine (IL-2)-activated killer (LAK) cells by human blood monocytes.
Singh SM; Sone S; Inamura N; Ogura T
Int J Cancer; 1989 Jul; 44(1):170-6. PubMed ID: 2663733
[TBL] [Abstract][Full Text] [Related]
7. Augmentation of lymphokine-activated killer cell cytotoxicity by monoclonal antibodies against human small cell lung carcinoma.
Tong AW; Lee JC; Wang RM; Ordonez G; Stone MJ
Cancer Res; 1989 Aug; 49(15):4103-8. PubMed ID: 2545333
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-12-mediated killer activity in lung cancer patients.
Haku T; Yanagawa H; Nabioullin R; Takeuchi E; Sone S
Cytokine; 1997 Nov; 9(11):846-52. PubMed ID: 9367545
[TBL] [Abstract][Full Text] [Related]
9. Heterogeneity of human lymphokine (IL-2)-activated killer (LAK) precursors and regulation of their LAK induction by blood monocytes.
Sone S; Inamura N; Nii A; Ogura T
Int J Cancer; 1988 Sep; 42(3):428-34. PubMed ID: 3262092
[TBL] [Abstract][Full Text] [Related]
10. Inhibition by fibrin coagulation of lung cancer cell destruction by human interleukin-2-activated killer cells.
Atagi S; Sone S; Fukuta K; Ogura T
Jpn J Cancer Res; 1992 Oct; 83(10):1088-94. PubMed ID: 1452461
[TBL] [Abstract][Full Text] [Related]
11. In vivo boosting of lung natural killer and lymphokine-activated killer cell activity by interleukin-2: comparison of systemic, intrapleural and inhalation routes.
Flexman JP; Manning LS; Robinson BW
Clin Exp Immunol; 1990 Oct; 82(1):151-6. PubMed ID: 2208789
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxicity against autologous, allogeneic, and xenogeneic tumor targets by human recombinant interleukin-2-activated lymphocytes from healthy dogs and dogs with lung tumors.
Mitchell DH; Withrow SJ; Johnston MR; Kruse CA
Am J Vet Res; 1991 Jul; 52(7):1132-6. PubMed ID: 1892269
[TBL] [Abstract][Full Text] [Related]
13. Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer.
Baxevanis CN; Reclos GJ; Gritzapis AD; Dedousis GV; Missitzis I; Papamichail M
Cancer; 1993 Jul; 72(2):491-501. PubMed ID: 8319179
[TBL] [Abstract][Full Text] [Related]
14. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
Colquhoun SD; Economou JS; Shau H; Golub SH
J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167
[TBL] [Abstract][Full Text] [Related]
15. In vitro natural killer and lymphokine-activated killer activity in patients with bronchogenic carcinoma.
Dunlap NE; Lane VG; Cloud GA; Tilden AB
Cancer; 1990 Oct; 66(7):1499-504. PubMed ID: 1698527
[TBL] [Abstract][Full Text] [Related]
16. Autologous bone marrow purging by in situ IL-2 activation of endogenous killer cells.
Margolin KA; Wright C; Forman SJ
Leukemia; 1997 May; 11(5):723-8. PubMed ID: 9180298
[TBL] [Abstract][Full Text] [Related]
17. Effector function of lymphokine-activated killer cells and cytotoxic T lymphocytes in ovarian epithelial carcinoma.
Lentz SS; Kovach JS; McKean DJ; Wieand HS; Podratz KC
Gynecol Oncol; 1990 Aug; 38(2):191-6. PubMed ID: 2387535
[TBL] [Abstract][Full Text] [Related]
18. Up-regulation of induction of lymphokine (IL-2)-activated killer (LAK) cell activity by FK-565 and cisplatin.
Basu S; Sodhi A; Singh SM; Suresh A
Immunol Lett; 1991 Mar; 27(3):199-204. PubMed ID: 2060971
[TBL] [Abstract][Full Text] [Related]
19. ICAM-1 expression by lung cancer cell lines: effects of upregulation by cytokines on the interaction with LAK cells.
Melis M; Spatafora M; Melodia A; Pace E; Gjomarkaj M; Merendino AM; Bonsignore G
Eur Respir J; 1996 Sep; 9(9):1831-8. PubMed ID: 8880099
[TBL] [Abstract][Full Text] [Related]
20. Induction of lymphokine-activated killer activities in peripheral blood lymphocytes and regional lymph node lymphocytes against PC-9 cultured adenocarcinoma and autologous pulmonary adenocarcinoma cells.
Morikawa Y; Watanabe S; Kodama T
Jpn J Clin Oncol; 1987 Jun; 17(2):129-39. PubMed ID: 3497285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
